Approval · Notice of Compliance 12462 · 2011
TEVA-REPAGLINIDE: Notice of Compliance 12462
Issued June 23, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12462
- Date
- June 23, 2011
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Oral antidiabetic agent
- Canadian reference product
- GLUCONORM (Novo Nordisk Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-REPAGLINIDE | 02366347 | Cancelled Pre Market |
| TEVA-REPAGLINIDE | 02366355 | Cancelled Pre Market |
| TEVA-REPAGLINIDE | 02366363 | Cancelled Pre Market |
Medicinal ingredients
- REPAGLINIDE 0.5 MG per TAB
- REPAGLINIDE 1 MG per TAB
- REPAGLINIDE 2 MG per TAB